1. Home
  2. ACET

as 06-13-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Founded: 1947 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 122.4M IPO Year: N/A
Target Price: $15.17 AVG Volume (30 days): 1.2M
Analyst Decision: Strong Buy Number of Analysts: 7
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.94 EPS Growth: N/A
52 Week Low/High: $1.10 - $4.81 Next Earning Date: 08-07-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

ACET Daily Stock ML Predictions

Stock Insider Trading Activity of Adicet Bio Inc. (ACET)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
GORDON CARL L ACET Director10% Owner Jan 25 '24 Buy $2.40 1,841,100 $4,418,640.00 7,526,359 SEC Form 4
GORDON CARL L ACET Director10% Owner Jan 25 '24 Buy $2.40 242,200 $581,280.00 990,254 SEC Form 4
GORDON CARL L ACET Director10% Owner Jan 25 '24 Buy $2.40 1,041,700 $2,500,080.00 1,255,985 SEC Form 4

Share on Social Networks: